Correction: "Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma," (Proc Natl Acad Sci USA (2014) 111, 44 (E4762-E4768) DOI: 10.1073/pnas.1405423111);Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for kaposi sarcoma herpesvirus lymphoma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 44, 2014, Pages 4762-4768

  Yanga, Dongmei ^a   Chena, Wuguo ^a   Xiongb, Jie ^b   Sherroda, Carly J ^a   Henryc, David H ^c   Dittmera, Dirk P ^a,b  

^a School of Veterinary Medicine   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; IRAK1 PROTEIN, HUMAN; MYD88 PROTEIN, HUMAN; TOLL LIKE RECEPTOR; TUMOR PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SEQUENCE; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; MISSENSE MUTATION; PRIMARY EFFUSION LYMPHOMA; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; WALDENSTROEM MACROGLOBULINEMIA; X CHROMOSOME; GENETICS; HERPES VIRUS INFECTION; METABOLISM; MUTATION; PATHOLOGY; TUMOR CELL LINE; VIROLOGY;

HERPESVIRIDAE; HUMAN HERPESVIRUS 8;

CELL LINE, TUMOR; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HUMANS; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; LYMPHOMA, PRIMARY EFFUSION; MUTATION; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; WALDENSTROM MACROGLOBULINEMIA;

EID: 84914685684     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1505880112     Document Type: Erratum

References (36)

1. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM (1995) Kaposi's sarcomaassociated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332(18):1186-1191.
2. Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF (2009) HIV-associated lymphomas and gamma-herpesviruses. Blood 113(6):1213-1224.
3. Staudt MR, et al. (2004) The tumor microenvironment controls primary effusion lymphoma growth in vivo. Cancer Res 64(14):4790-4799.
4. Boshoff C, et al. (1998) Establishing a KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. Blood 91(5):1671-1679.
5. Roy D, Sin SH, Damania B, Dittmer DP (2011) Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines. Blood 118(7):e32-e39.
6. Klein U, et al. (2003) Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 101(10):4115-4121.
7. Tarpey PS, et al. (2009) A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. Nat Genet 41(5):535-543.
8. Bentley DR, et al. (2008) Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456(7218):53-59.
9. Fan W, et al. (2005) Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association. J Virol 79(2): 1244-1251.
10. Cao Z, Henzel WJ, Gao X (1996) IRAK: A kinase associated with the interleukin-1 receptor. Science 271(5252):1128-1131.
11. Kollewe C, et al. (2004) Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling. J Biol Chem 279(7):5227-5236.
12. Jones KD, et al. (1999) Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood 94(8):2871-2879.
13. O'Hara AJ, Vahrson W, Dittmer DP (2008) Gene alteration and precursor and mature microRNA transcription changes contribute to the miRNA signature of primary effusion lymphoma. Blood 111(4):2347-2353.
14. Gaidano G, et al. (1999) Genetic characterization of HHV-8/KSHV-positive primary effusion lymphoma reveals frequent mutations of BCL6: Implications for disease pathogenesis and histogenesis. Genes Chromosomes Cancer 24(1):16-23.
15. Boulanger E, et al. (2001) A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients. Hematol J 2(3):172-179.
16. Mullaney BP, Ng VL, Herndier BG, McGrath MS, Pallavicini MG (2000) Comparative genomic analyses of primary effusion lymphoma. Arch Pathol Lab Med 124(6): 824-826.
17. Ohshima K, et al. (2002) Chromosomal and comparative genomic analyses of HHV-8-negative primary effusion lymphoma in five HIV-negative Japanese patients. Leuk Lymphoma 43(3):595-601.
18. Nair P, Pan H, Stallings RL, Gao SJ (2006) Recurrent genomic imbalances in primary effusion lymphomas. Cancer Genet Cytogenet 171(2):119-121.
19. Luan SL, et al. (2010) Primary effusion lymphoma: Genomic profiling revealed amplification of SELPLG and CORO1C encoding for proteins important for cell migration. J Pathol 222(2):166-179.
20. Richter J, et al.; ICGC MMML-Seq Project (2012) Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 44(12):1316-1320.
21. Schmitz R, et al. (2012) Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490(7418):116-120.
22. Love C, et al. (2012) The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 44(12):1321-1325.
23. Luftig M, et al. (2003) Epstein-Barr virus latent membrane protein 1 activation of NF-kappaB through IRAK1 and TRAF6. Proc Natl Acad Sci USA 100(26):15595-15600.
24. Camcioglu Y, et al. (2004) HHV-8-associated Kaposi sarcoma in a child with IFNgammaR1 deficiency. J Pediatr 144(4):519-523.
25. Byun M, et al. (2010) Whole-exome sequencing-based discovery of STIM1 deficiency in a child with fatal classic Kaposi sarcoma. J Exp Med 207(11):2307-2312.
26. Gregory SM, et al. (2009) Toll-like receptor signaling controls reactivation of KSHV from latency. Proc Natl Acad Sci USA 106(28):11725-11730.
27. Sin SH, Dittmer DP (2013) Viral latency locus augments B-cell response in vivo to induce chronic marginal zone enlargement, plasma cell hyperplasia, and lymphoma. Blood 121(15):2952-2963.
28. Abend JR, et al. (2012) Kaposi's sarcoma-associated herpesvirus microRNAs target IRAK1 and MYD88, two components of the toll-like receptor/interleukin-1R signaling cascade, to reduce inflammatory-cytokine expression. J Virol 86(21):11663-11674.
29. Jacob CO, et al. (2009) Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci USA 106(15): 6256-6261.
30. Ngo VN, et al. (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470(7332):115-119.
31. Treon SP, et al. (2012) MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med 367(9):826-833.
32. Landgren O, Staudt L (2012) MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med 367(23):2255-2256, author reply 2256-2257.
33. Yang G, et al. (2013) A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood 122(7):1222-1232.
34. Rhyasen GW, et al. (2013) Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell 24(1):90-104.
35. Tewhey R, et al. (2009) Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nat Biotechnol 27(11):1025-1031.
36. Altshuler D, et al. (2000) An SNP map of the human genome generated by reduced representation shotgun sequencing. Nature 407(6803):513-516.